Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the stock.

Several other research analysts have also issued reports on the company. Lake Street Capital cut their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a report on Tuesday, March 4th.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $0.38 on Friday. The stock has a market capitalization of $10.66 million, a price-to-earnings ratio of -0.58 and a beta of 1.33. Ekso Bionics has a 52-week low of $0.34 and a 52-week high of $1.53. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock’s 50 day moving average price is $0.46 and its two-hundred day moving average price is $0.67.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. On average, equities analysts predict that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.